Today's Guest: Gabriel Steg
Robert Califf, MD: Hello. I'm Rob Califf. I want to welcome you to a new edition of Life and Times of Leading Cardiologists. As all of you know, this is a show where I learn a lot by talking to people whom I respect greatly. But we also hope to give inspiration to others about how to become excellent in cardiology and in life in general.
I'm here at the European Society of Cardiology (ESC) meeting, and I'm really pleased to have Gabriel Steg with me. He's a colleague and a very excellent interventional cardiologist in clinical trials and a highly respected person in the cardiovascular community. Gabriel just told me that at the ESC, they were expecting a smaller number of attendees than usual, but they've actually exceeded last year. They've run out of programs. This is really a major meeting. So welcome to the show.
Philippe Gabriel Steg, MD: Thank you.
Origins: Overcoming the Past
Dr. Califf:I would like to start out with origins. And I'll approach this as an American. I think France, to most Americans, is a bit of a mysterious place. George Bush could never really understand it. And we have a lot of interesting things that we say about it.
COMMENTARY
Life and Times of Leading Cardiologists. Guest: Gabriel Steg
Robert Califf, MD; Philippe Gabriel Steg, MD
DisclosuresOctober 22, 2013
Today's Guest: Gabriel Steg
Robert Califf, MD: Hello. I'm Rob Califf. I want to welcome you to a new edition of Life and Times of Leading Cardiologists. As all of you know, this is a show where I learn a lot by talking to people whom I respect greatly. But we also hope to give inspiration to others about how to become excellent in cardiology and in life in general.
I'm here at the European Society of Cardiology (ESC) meeting, and I'm really pleased to have Gabriel Steg with me. He's a colleague and a very excellent interventional cardiologist in clinical trials and a highly respected person in the cardiovascular community. Gabriel just told me that at the ESC, they were expecting a smaller number of attendees than usual, but they've actually exceeded last year. They've run out of programs. This is really a major meeting. So welcome to the show.
Philippe Gabriel Steg, MD: Thank you.
Origins: Overcoming the Past
Dr. Califf:I would like to start out with origins. And I'll approach this as an American. I think France, to most Americans, is a bit of a mysterious place. George Bush could never really understand it. And we have a lot of interesting things that we say about it.
© 2013 WebMD, LLC
Cite this: Life and Times of Leading Cardiologists. Guest: Gabriel Steg - Medscape - Oct 22, 2013.
Tables
Authors and Disclosures
Authors and Disclosures
Authors
Robert Califf, MD
Professor of Medicine; Donald F. Fortin Professor, Cardiology; Vice Chancellor for Clinical Research; Director, Duke Translational Medicine Institute, Duke University Medical Center, Durham, North Carolina
Disclosure: Dr. Robert Califf has disclosed the following relevant financial relationships:
Performed consulting or other services (including CME) for Medscape LLC/theheart.org and Genentech
Philippe Gabriel Steg, MD
Director, Coronary Care Unit, Hôpital Bichat; Professor, Département Hospitalo-Universitaire FIRE, Université Paris-Diderot; Inserm Unit 698, Paris, France; Professor, National Heart & Lung Institute, Imperial College, London, United Kingdom
Disclosure: Philippe Gabriel Steg, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amarin Corporation plc; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers-Squibb Company; Daiichi Sankyo-Lilly; GlaxoSmithKline; Medtronic, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc; sanofi-aventis; SERVIER; The Medicines Company; Vivus
Served as a speaker or a member of a speakers bureau for: Amarin Corporation plc; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers-Squibb Company; Daiichi Sankyo-Lilly; GlaxoSmithKline; Medtronic, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc; sanofi-aventis; SERVIER; The Medicines Company; Vivus
Received grants for clinical research from: New York University School of Medicine; sanofi-aventis; SERVIER
Owns stock, stock options, or bonds from: Aterovax